BNGO Stock Overview
Bionano Genomics, Inc. provides genome analysis software solutions.
Bionano Genomics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.41|
|52 Week High||US$6.37|
|52 Week Low||US$1.16|
|1 Month Change||47.85%|
|3 Month Change||75.91%|
|1 Year Change||-61.87%|
|3 Year Change||26.84%|
|5 Year Change||n/a|
|Change since IPO||-65.52%|
Recent News & Updates
Bionano stock down ~8% after hours; co reports Q2 revenue beat, wider loss
Shares of small-cap pharmaceutical company Bionano Genomics (NASDAQ:BNGO) fell 8.1% to $2.16 in Thursday postmarket trading, after the genome analysis firm reported a wider Q2 loss and a significant fall in quarterly gross margin. It is worth noting that BNGO stock had gained 27% since Tuesday and posted a three-day winning streak at today's close. BNGO announced Q2 net loss of $32.16M compared to a loss of $18.79M last year. However, its revenue of $6.67M grew a healthy 72.8% Y/Y and beat estimates by $0.39M. The company said the quarterly figure was an all-time high for it. Revenue growth was aided by expansion of the installed base of BNGO's Saphyr sytems and a 24% Y/Y rise in sales of nanochannel array flowcells. The company's bottom line was hurt due to a 87.2% Y/Y rise in total operating expenses to $33.55M. BNGO CEO Erik Holmlin said that the company remained on track to achieve its previously outlined ELEVATE! milestones for the second half of the year. Bionano Geonomics (BNGO) stock has lost 21.4% YTD.
Bionano gets US patent for analysis of nucleic acid fragments for genetic abnormalities
Bionano Genomics (NASDAQ:BNGO) said the U.S. Patent and Trademark Office issued a patent related to methods claiming the use of certain nanochannel arrays to detect and quantitate genetic abnormalities. The U.S. patent No.11,359,244 titled Characterization of Molecules in Nanofluidics, claims methods for analyzing small nucleic acid fragments in nanochannel arrays, which Bionano has used to analyze ultra-high molecular weight (UHMW) DNA for the identification of structural variants (SVs) as part of its Saphyr system, the company said in a June 29 press release. Bionano added the methods claim the use of certain nanochannel arrays to detect and quantitate genetic abnormalities, including a DNA translocation, amplification, inversion, and sex chromosome aneuploidy, among other things. The company said it believes that the methods in the patent may one day support the commercialization of assays directed to non-invasive prenatal testing (NIPT) in maternal fetal medicine or ctDNA in oncology. BNGO +2.11% to $1.45 premarket June 29
|BNGO||US Life Sciences||US Market|
Return vs Industry: BNGO underperformed the US Life Sciences industry which returned -20.5% over the past year.
Return vs Market: BNGO underperformed the US Market which returned -12.9% over the past year.
|BNGO Average Weekly Movement||14.7%|
|Life Sciences Industry Average Movement||11.1%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.1%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: BNGO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: BNGO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.
Bionano Genomics Fundamentals Summary
|BNGO fundamental statistics|
Is BNGO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BNGO income statement (TTM)|
|Cost of Revenue||US$19.60m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.36|
|Net Profit Margin||-453.69%|
How did BNGO perform over the long term?See historical performance and comparison
Is BNGO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BNGO?
Other financial metrics that can be useful for relative valuation.
|What is BNGO's n/a Ratio?|
Price to Sales Ratio vs Peers
How does BNGO's PS Ratio compare to its peers?
|BNGO PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
NSTG NanoString Technologies
ADPT Adaptive Biotechnologies
BNGO Bionano Genomics
Price-To-Sales vs Peers: BNGO is expensive based on its Price-To-Sales Ratio (30x) compared to the peer average (6.3x).
Price to Earnings Ratio vs Industry
How does BNGO's PE Ratio compare vs other companies in the US Life Sciences Industry?
Price-To-Sales vs Industry: BNGO is expensive based on its Price-To-Sales Ratio (30x) compared to the US Life Sciences industry average (5.3x)
Price to Sales Ratio vs Fair Ratio
What is BNGO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||30x|
|Fair PS Ratio||14.6x|
Price-To-Sales vs Fair Ratio: BNGO is expensive based on its Price-To-Sales Ratio (30x) compared to the estimated Fair Price-To-Sales Ratio (14.6x).
Share Price vs Fair Value
What is the Fair Price of BNGO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BNGO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BNGO's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Bionano Genomics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BNGO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BNGO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BNGO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BNGO's revenue (59.7% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: BNGO's revenue (59.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BNGO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Bionano Genomics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BNGO is currently unprofitable.
Growing Profit Margin: BNGO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BNGO is unprofitable, and losses have increased over the past 5 years at a rate of 38.7% per year.
Accelerating Growth: Unable to compare BNGO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BNGO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (15.9%).
Return on Equity
High ROE: BNGO has a negative Return on Equity (-37.16%), as it is currently unprofitable.
Discover strong past performing companies
How is Bionano Genomics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BNGO's short term assets ($216.3M) exceed its short term liabilities ($27.9M).
Long Term Liabilities: BNGO's short term assets ($216.3M) exceed its long term liabilities ($8.9M).
Debt to Equity History and Analysis
Debt Level: BNGO is debt free.
Reducing Debt: BNGO currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BNGO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BNGO has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 34.5% each year.
Discover healthy companies
What is Bionano Genomics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BNGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BNGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BNGO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BNGO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BNGO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Robert Holmlin (54 yo)
Dr. Robert Erik Holmlin, Ph D., M.B.A. has been the Chief Executive Officer and President of BioNano Genomics, Inc. (alternatively BioNanomatrix, Inc.) since January 12, 2011 and serves as its Secretary. D...
CEO Compensation Analysis
Compensation vs Market: Robert's total compensation ($USD7.58M) is above average for companies of similar size in the US market ($USD3.94M).
Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.
Experienced Management: BNGO's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: BNGO's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BNGO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.9%.
Bionano Genomics, Inc.'s employee growth, exchange listings and data sources
- Name: Bionano Genomics, Inc.
- Ticker: BNGO
- Exchange: NasdaqCM
- Founded: 2003
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$699.237m
- Shares outstanding: 290.14m
- Website: https://www.bionanogenomics.com
Number of Employees
- Bionano Genomics, Inc.
- 9540 Towne Centre Drive
- Suite 100
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/07 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.